Predicted protein targets (top 17)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SRD5A1 | P18405 | 1/20 | 0.55 |
| ▸ | SRD5A2 | P31213 | 1/20 | 0.54 |
| ▸ | LMNA | P02545 | 2/20 | 0.53 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.53 |
| ▸ | CASP3 | P42574 | 1/20 | 0.53 |
| ▸ | SENP8 | Q96LD8 | 1/20 | 0.53 |
| ▸ | SENP6 | Q9GZR1 | 1/20 | 0.53 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.53 |
| ▸ | EPHX2 | P34913 | 7/20 | 0.50 |
| ▸ | FAAH | O00519 | 2/20 | 0.50 |
| ▸ | MAPT | P10636 | 2/20 | 0.46 |
| ▸ | HRH3 | Q9Y5N1 | 1/20 | 0.46 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.46 |
| ▸ | CYP2J2 | P51589 | 1/20 | 0.46 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.46 |
| ▸ | MEN1 | O00255 | 2/20 | 0.46 |
| ▸ | PARP10 | Q53GL7 | 1/20 | 0.45 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3458790 | 0.83 | SRD5A1 (0.59) | SRD5A1SRD5A2LMNAALDH1A1CASP3 | |
| SCHEMBL1977190 | 0.81 | ALDH1A1 (0.70) | SRD5A1SRD5A2LMNAALDH1A1CASP3 | |
| SCHEMBL4682743 | 0.80 | SRD5A1 (0.67) | SRD5A1SRD5A2LMNAALDH1A1CASP3 | |
| SCHEMBL4228646 | 0.79 | HRH3 (0.70) | SRD5A1HRH3 | |
| SCHEMBL25933641 | 0.79 | HRH3 (0.61) | SRD5A1SRD5A2LMNAALDH1A1CASP3 | |
| SCHEMBL17869370 | 0.79 | ALDH1A1 (0.55) | SRD5A1SRD5A2LMNAALDH1A1CASP3 | |
| SCHEMBL22664149 | 0.79 | ALDH1A1 (0.55) | SRD5A1SRD5A2LMNAALDH1A1CASP3 | |
| SCHEMBL13699090 | 0.79 | ALDH1A1 (0.59) | SRD5A1SRD5A2LMNAALDH1A1CASP3 | |
| SCHEMBL27725664 | 0.79 | ALDH1A1 (0.59) | SRD5A1SRD5A2LMNAALDH1A1CASP3 | |
| SCHEMBL14413606 | 0.78 | SRD5A1 (0.64) | SRD5A1SRD5A2LMNAALDH1A1CASP3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20090233910-A1 | Npy antagonists, preparation and uses | CEREP (FR) | 2009-09-17 | — | — | US | disclosed |
| US-20090233910-A1 | Npy antagonists, preparation and uses | CEREP (FR) | 2009-09-17 | — | — | US | disclosed |
| US-20090233910-A1 | Npy antagonists, preparation and uses | CEREP (FR) | 2009-09-17 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090233910-A1 | Npy antagonists, preparation and uses | NPY1R, NPY5R, NPY2R | SRD5A1 2198/4885SRD5A2 2351/4885LMNA 2227/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.